Dr. Song Liu Song Liu, PhD

Song Liu

PhD

Special Interests:

Translational Bioinformatics Biomarker Discovery Companion Diagnostics Cancer Therapeutics Precision Medicine Immuno-Oncology

About Song Liu

Biography:

I graduated from the University of Science and Technology of China in 2002. I obtained my PhD from The State University of New York at Buffalo in 2006, and received the post-doctoral training at Howard Hughes Medical Institute (HHMI) at Columbia University.

I was appointed to an Assistant Professor position at Roswell Park Comprehensive Cancer Center in 2009, an Associate Professor position in 2012, and a Full Professor position in 2016.

I completed the General Management Program at the Wharton School of Business, University of Pennsylvania in 2018 (WMP’18).

Positions

Roswell Park Comprehensive Cancer Center
  • Professor of Oncology & Vice Chair
  • Department of Biostatistics and Bioinformatics

Background

Education and Training:

  • BS - 2002 - University of Science and Technology of China
  • PhD - 2006 - State University of New York at Buffalo
  • Executive Education: General Management Program - Wharton School of Business, University of Pennsylvania

Fellowship:

  • Post-doctoral Fellow - Howard Hughes Medical Institute (HHMI) at Columbia University

Professional Memberships:

  • American Association for Cancer Research (AACR)
  • Society for Immunotherapy of Cancer (SITC)

Research

Research Overview:

I am a Professor and Vice Chair of the Department of Biostatistics and Bioinformatics at Roswell Park Comprehensive Cancer Center. My research revolves around the development and application of computational methods to address biologically important and clinically significant questions in cancer diagnosis and treatment.

I am currently one of the Principal Investigators of the Data Management and Resource-Sharing Center for the Immuno-Oncology Translational Network (IOTN), an NCI-funded Cancer Moonshot flagship initiative devoted to cancer immunotherapy. I am also one of the Principal Investigators of the Coordination Center for the Drug Resistance and Sensitivity Network (DRSN), an NCI-funded Cancer Moonshot flagship initiative devoted to innovative strategies to understand and combat mechanisms of tumor resistance and to exploit tumor sensitivity to anti-cancer therapies.

I am the founding director of the Roswell Park CCSG Bioinformatics Core. I co-lead the Biostatistics and Bioinformatics Core of an NCI-funded Cancer Immunotherapy P01 Program, which focuses on targeting the chemokine system to sensitize tumors to immunotherapy.

I am the author of more than 200 peer-reviewed publications, which have been cited over 10,000 times. I am an Associate Editors-in-Chief of Genomics, Proteomics & Bioinformatics (GPB).


Publications

Full Publications list on PubMed

Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K. Efficacy and Safety of Pembrolizumab in Combination with Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncology 2020 Nov 19. doi: 10.1001/jamaoncol.2020.5945. Online ahead of print. 

Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, Rech AJ, Zaretsky JM, Comin-Anduix B, Ng A, Chour W, Yu TV, Rizvi H, Chen JM, Manning P, Steiner GM, Doan XC, Tumor Neoantigen Selection Alliance; Merghoub T, Guinney J, Kolom A, Selinsky C, Ribas A, Hellmann MD, Hacohen N, Sette A, Heath JR, Bhardwaj N, Ramsdell F, Schreiber RD, Schumacher TN, Kvistborg P, Defranoux NA. Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell 2020 29;183(3):818-834.e13.  

Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Oba T, Long MD, Keler T, Marsh HC, Minderman H, Abrams SI*, Liu S*, Ito F. Nature Communications 2020;11(1):5415. (*: joint supervising authors). 

Zhang D, Hu Q, Liu X, Ji Y, Chao HP, Liu Y, Tracz A, Kirk J, Buonamici S, Zhu P, Wang J, Liu S*, Tang DG*. Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Nature Communications 2020;11(1):2089 (*: joint corresponding authors). 

Phillips JW, Pan Y, Tsai BL, Xie Z, Demirdjian L, Xiao W, Yang HT, Zhang Y, Lin CH, Cheng D, Hu Q, Liu S, Black DL, Witte ON, Xing Y. Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers. Proceedings of the National Academy of Sciences 2020;117(10):5269-5279.  

Li W, Zhang N, Jin C, Long MD, Rajabi H, Yasumizu Y, Fushimi A, Yamashita N, Hagiwara M, Zheng R, Wang J, Kui L, Singh H, Kharbanda S, Hu Q, Liu S, Kufe D. MUC1-C drives stemness in progression of colitis to colorectal cancer. JCI Insight 2020;5(12):e137112.

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment